Timothy S. Gardner, PhD, Director, Research Programs & OperationsAmyris, Inc.
Dr. Timothy Gardner is the Director of Research Programs & Operations at Amyris, where leads strain and process development for the commercial production of farnesene. Farnesene is the base molecule for Amyris’ renewable diesel fuel, lubricant, cosmetic oil and polymer products. Amyris’ products include the world’s first semi-synthetic Artemisinin drug to treat Malaria, and Diesel de Cana a high-performance diesel fuel made from sugarcane.
Dr. Gardner received his B.S. in Mechanical Engineering from Princeton University in 1995 and his Ph.D. in Biomedical Engineering from Boston University in 2000. His pioneering demonstration of a genetic flip-flop in Escherichia coli helped to launch the field of synthetic biology. In the spring of 2000, he co-founded Cellicon Biotechnologies, a company developing improved antibiotics through the mapping and control of cellular gene circuitry. In 2003, Dr. Gardner was appointed Assistant Professor of Biomedical Engineering at Boston University and is currently on leave. Dr. Gardner is the recipient of a 2004 Technology Review Magazine TR100 award honoring a group of 100 creative individuals under age 35, whose research will shape how we live and work in the future. His work has also been recognized by Scientific American, the New Scientist, and the New York Times.Listen to an interview with Tim